GlaxoSmithKline Files for Approval of Melanoma Drug Combo


Jul 10, 2013


GlaxoSmithKline has filed for U.S. approval of a two-drug combination against melanoma earlier than some analysts expected. Britain's biggest pharmaceuticals group said it had submitted the combination of dabrafenib and trametinib to the U.S. FDA based on data from a Phase I/II study. Read more
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments